The work performed in this thesis addresses some of the challenges facing multidisciplinary tumor boards (MDT) when assessing patients who present with a non-metastatic non-small cell lung cancer (NSCLC). Challenges in patients with early-stage NSCLC treated with stereotactic ablative radiotherapy Acute and late fibrotic changes following stereotactic ablative radiotherapy (SABR) are commonly observed, and mass-like fibrosis is sometimes difficult to distinguish from tumor recurrence. An overview of the patterns of radiological changes seen after SABR were highlighted, and high-risk radiological features (HRF’s) associated with a higher risk of tumor recurrence were presented. In addition, the incidence and patterns of change of HRF’s were ...
BACKGROUND: The practice of treating a solitary pulmonary nodule (SPN) suspicious for stage I non-sm...
For early-stage and medically inoperable non-small-cell lung carcinoma (NSCLC) patients, stereotacti...
INTRODUCTION: There is some evidence to suggest that patients with underlying pulmonary fibrosis (PF...
Background Practice guidelines have been developed for early-stage and locally advanced non-small ce...
none9noBackground: Parenchymal changes after stereotactic body radiation therapy (SBRT) make differe...
BACKGROUND: Practice guidelines have been developed for early-stage and locally advanced non-small c...
BackgroundThe use of stereotactic ablative radiotherapy (SABR) as primary treatment for early stage ...
Lung cancer is one of the leading causes of death worldwide, and it is the largest contributor to ne...
Non-small cell lung cancer (NSCLC) accounts for approximately one in five cancer-related deaths, and...
Introduction: Surgery is the standard treatment for early stage non-small-cell lung cancer (NSCLC). ...
PURPOSE Imaging after stereotactic ablative radiation therapy (SABR) for early-stage non-small cell...
Non-small cell lung cancer (NSCLC) accounts for approximately one in five cancer-related deaths, and...
PURPOSE: To investigate, in the setting of stereotactic ablative radiation therapy (SABR) for early-...
IntroductionSurgery is the standard treatment for early stage non–small-cell lung cancer (NSCLC). Fo...
BACKGROUND: The use of stereotactic ablative radiotherapy (SABR) as primary treatment for early stag...
BACKGROUND: The practice of treating a solitary pulmonary nodule (SPN) suspicious for stage I non-sm...
For early-stage and medically inoperable non-small-cell lung carcinoma (NSCLC) patients, stereotacti...
INTRODUCTION: There is some evidence to suggest that patients with underlying pulmonary fibrosis (PF...
Background Practice guidelines have been developed for early-stage and locally advanced non-small ce...
none9noBackground: Parenchymal changes after stereotactic body radiation therapy (SBRT) make differe...
BACKGROUND: Practice guidelines have been developed for early-stage and locally advanced non-small c...
BackgroundThe use of stereotactic ablative radiotherapy (SABR) as primary treatment for early stage ...
Lung cancer is one of the leading causes of death worldwide, and it is the largest contributor to ne...
Non-small cell lung cancer (NSCLC) accounts for approximately one in five cancer-related deaths, and...
Introduction: Surgery is the standard treatment for early stage non-small-cell lung cancer (NSCLC). ...
PURPOSE Imaging after stereotactic ablative radiation therapy (SABR) for early-stage non-small cell...
Non-small cell lung cancer (NSCLC) accounts for approximately one in five cancer-related deaths, and...
PURPOSE: To investigate, in the setting of stereotactic ablative radiation therapy (SABR) for early-...
IntroductionSurgery is the standard treatment for early stage non–small-cell lung cancer (NSCLC). Fo...
BACKGROUND: The use of stereotactic ablative radiotherapy (SABR) as primary treatment for early stag...
BACKGROUND: The practice of treating a solitary pulmonary nodule (SPN) suspicious for stage I non-sm...
For early-stage and medically inoperable non-small-cell lung carcinoma (NSCLC) patients, stereotacti...
INTRODUCTION: There is some evidence to suggest that patients with underlying pulmonary fibrosis (PF...